Prevalence and factors associated with multidrug resistant Mycobacterium tuberculosis infection in Cameroon: a systematic review and meta-analysis

Publication date: Jul 14, 2026

BackgroundMultidrug-resistant tuberculosis (MDR-TB) remains a significant public health threat in low-and middle-income countries, including Cameroon. This systematic review and meta-analysis aimed to determine the pooled prevalence of MDR-TB and other specific anti-tuberculosis drug resistance patterns, as well as to identify factors associated with drug-resistant tuberculosis in Cameroon. MethodsA comprehensive literature search was conducted in PubMed, Scopus, Web of Science, Embase, Cochrane Library, and African Journals Online. Additional studies were identified through Google Scholar and reference list screening. Observational studies (cross-sectional, cohort, and case-control) reporting drug resistance among bacteriologically confirmed tuberculosis patients in Cameroon were eligible. Joanna Briggs Institute critical appraisal tools were used to critically assessed the study quality. Pooled prevalence estimates were calculated using random-effects meta-analysis. Subgroup analyses and meta-regression explored sources of heterogeneity. A p-value 11 0.05 was considered statistically significant. ResultsTwenty-eight studies conducted between 1995 and 2022 were included. The pooled prevalence of MDR-TB was 5.2% (95% CI: 2.7-9.6; 21 studies; n = 7,515), with significantly higher acquired resistance (11.6%; 95% CI: 6.3-20.3) than initial resistance (2.0%; 95% CI: 1.1-3.5). The highest pooled MDR-TB prevalence was observed in the most recent studies (38.8%; 95% CI: 33.7-44.2), and the lowest in 2015-2019 (2.7%; 95% CI: 0.4-15.2). Any resistance to anti-tuberculosis drugs was 16.0% (95% CI: 10.3-23.9; 28 studies; n = 9,931), and rifampicin resistance was 4.6% (95% CI: 2.4-8.6; 25 studies; n = 8,728). Monoresistance was highest for streptomycin (6.4%; 95% CI: 3.7-10.8) and isoniazid (4.7%; 95% CI: 3.0-7.4). Previous tuberculosis infection was the strongest predictor of drug resistance (OR = 3.9; 95% CI: 1.8-8.4), followed by alcohol consumption (OR = 1.8; 95% CI: 1.2-2.7) and history of incarceration (OR = 1.7; 95% CI: 1.1-2.6). High heterogeneity was observed across most of the pooled estimates. ConclusionsDrug-resistant tuberculosis, particularly MDR-TB, poses a substantial burden in Cameroon, with acquired resistance significantly exceeding initial resistance. Previous tuberculosis infection, alcohol use, and incarceration are key modifiable risk factors. These findings underscore the urgent need to strengthen routine drug susceptibility testing, scale up rapid molecular diagnostics, enhance treatment adherence strategies, and implement targeted interventions for high-risk populations.

PDF

Concepts Keywords
Cameroon
Ci
Drug
Factors
Infection
Mdr
Medrxiv
Meta
Pooled
Preprint
Prevalence
Resistance
Resistant
Risk
Tuberculosis

Semantics

Type Source Name
disease MESH Mycobacterium tuberculosis infection
pathway KEGG Tuberculosis
disease MESH drug-resistant tuberculosis
disease MESH included
drug DRUGBANK Rifampicin
drug DRUGBANK Streptomycin
drug DRUGBANK Isoniazid
disease MESH infection
drug DRUGBANK Ethanol
disease MESH MHAC
drug DRUGBANK Coenzyme M
drug DRUGBANK Spinosad
disease MESH co infection
disease MESH HIV infection
pathway REACTOME HIV Infection
drug DRUGBANK Dihydrostreptomycin

Download Document

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *